Director/PDMR Shareholding

GSK PLC

20 February 2025

 

GSK plc (the 'Company')
Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Following the vesting on 18 February 2025 of 50% of an award made on 18 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Tony Wood will receive a cash payment of £247,942.28 less applicable tax withholding in respect of 17,182.417 notional Ordinary Shares.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.4300	17,182.417
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	N/A

 

END